Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.

Infection in Solid Organ Transplant Recipients Clinical Trial

Official title:

Individualization of Ganciclovir and Valganciclovir Doses in Renal Transplant Patients for Prophylaxis or Treatment of Cytomegalovirus(CMV)Infection Using Bayesian Prediction.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01446445
• Other study ID #: GCV2010
• Secondary ID: 2010-021433-32
• Status: Completed
• Phase: Phase 4
• First received: September 19, 2011
• Last updated: March 25, 2015
• Start date: December 2011
• Est. completion date: August 2014

Study information

• Verified date: March 2015
• Source: Hospital Universitari de Bellvitge
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Agencia Española de Medicamentos y Productos Sanitarios
• Study type: Interventional

Clinical Trial Summary

The objective of the present study is to optimize intravenous ganciclovir(GCV) and oral valganciclovir (VGCV)doses, advised by the drug exposure, indicated by the area under the concentration time curve (AUC), in renal transplant patients receiving oral VGCV or intravenous GCV for CMV prophylaxis or treatment. The initial doses will be calculated according to population pharmacokinetic model. Subsequent doses will be adjusted according to plasma GCV concentrations, using the Bayesian approach. This method of dose adjustments could lead to increase the percentage of patients achieving a therapeutic exposure.

Description:

The area under the concentration time curve of serum concentrations of GCV is an indicator of systemic exposure to the drug and is related to the effectiveness and safety. According to the population model developed by our group, less than 16% of patients treated achieve the therapeutic goal of AUC (40 to 50 mcg • h / L) after drug dosing according to summary of product characteristics (SPC). Especially, patients with impaired renal function values (creatinine clearance (CrC)l <30 ml / min) or high (CrCl> 70 ml / min) would be overdosed and underdosed, respectively, with the risk of more adverse effects or therapeutic failure.

Therefore, the individualization of the dosage of GCV, can contribute greatly to achieve optimal exposure to the drug in transplant patients, especially in the cases of extreme values of renal function (CrCl decreased and high). As a consequence, minimize adverse effects, ensure greater efficiency in the target population and reduce associated costs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: August 2014
• Est. primary completion date: August 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects must be 18 or older, weigh more than 34kg and may be of either sex and race.

• Subjects must be willing to give informed consent (IC) in writing and be able to do and follow the study. If a subject cannot give informed consent in writing , a legal representative could sign in his place.

• Women of childbearing potential should perform a pregnancy test at the time of entry and accept the use of a medically acceptable contraceptive method during the study.

Exclusion Criteria:

• Creatinine Clearance (CrCl )<10 mL / min.

• Subjects may not have a history of type I hypersensitivity or idiosyncratic reactions to drugs ganciclovir/valganciclovir

• Pregnancy women.

• Women breast feeding

• Subjects may not present at time of inclusion any clinically significant disease that could interfere with study evaluations.

• Previous participation in another clinical trial sponsored by pharmaceutical industry, in which the promoter and the protocol set which should be the treatment for CMV.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Infection in Solid Organ Transplant Recipients

Intervention

Drug:
• Ganciclovir/ Valganciclovir according to SPC
Doses according to Summaries of Product Characteristics (SPC)
• Ganciclovir/ Valganciclovir according to PK model
Doses according to population pharmacokinetic model

Locations

Country	Name	City	State
Spain	Nephrology Department- Hospital Universitari Bellvtge	L'Hospitalet de Llobregat	Barcelona

Sponsors (2)

Lead Sponsor	Collaborator
Nuria Lloberas	Ministerio de Sanidad, Servicios Sociales e Igualdad

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the concentration time curve (AUC)of ganciclovir in steady state	Values of AUC of ganciclovir achieved with each intervention, that is, ganciclovir and valganciclovir dose adjustment according to SPC(specific product characteristics) or PK (pharmacokinetic) model.; In each intervention: after starting treatment, change in route of administration, change in renal clearance >10 mL/min and end of treatment blood sampling for pharmacokinetic analysis will be performed in order to calculate AUC.	Change from baseline to the end of the treatment, with an expected average of treatment of 4 weeks in treatment and 90 days in prophylaxis patients.	No
Secondary	CMV viral load measured by quantitative polymerase chain reaction (PCR)	CMV viral load will be correlated with the exposure to ganciclovir during treatment period, in both interventions.	Change from baseline to day 30 of study entry	No
Secondary	CMV viral load measured by quantitative polymerase chain reaction (PCR)	CMV viral load will be correlated with the exposure to ganciclovir during treatment period, in both interventions.	Change from baseline to day 60 of study entry	No
Secondary	CMV viral load measured by quantitative polymerase chain reaction (PCR)	CMV viral load will be correlated with the exposure to ganciclovir during treatment period, in both interventions.	Change from baseline to day 90 of study entry	No
Secondary	T-cell immune response against CMV infection measured by Enzyme-linked immunosorbent spot (ELISPOT)	In prophylaxis patients(arm 1.A and 1.B): ELISPOT assay will be performed to assess the immune response to CMV viral infection on day 40 of initial dose and on day 20 after end of prophylactic therapy.	Change from day 40 of treatment to day 20 after end of treatment.	No
Secondary	T-cell immune response against CMV infection measured by Enzyme-linked immunosorbent spot (ELISPOT)	In treatment patients(arm 2.A and 2.B): ELISPOT assay will be performed to assess the immune response to CMV viral infection at baseline, day 10 and 20 of treatment.	Change from baseline to day 20 of treatment	No